Body Height of MPS I and II Patients after Hematopoietic Stem Cell Transplantation: The Impact of Dermatan Sulphate.

Patryk Lipiński Agnieszka Różdżyńska-Świątkowska Agnieszka ŁugowskaJolanta MaruchaKatarzyna Drabko Anna Tylki-Szymańska

Published in: Diagnostics (Basel, Switzerland) (2024)

Both MPS I and MPS II patients presented height gain after HSCT compared to the curves of untreated patients. The absence of dermatan sulphate after HSCT could lead to normal growth in bone length.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
prognostic factors
body mass index
hematopoietic stem cell